PSI Advisors LLC Acquires 107 Shares of Novo Nordisk A/S (NYSE:NVO)

PSI Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 53.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 307 shares of the company’s stock after acquiring an additional 107 shares during the period. PSI Advisors LLC’s holdings in Novo Nordisk A/S were worth $32,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Jennison Associates LLC lifted its stake in shares of Novo Nordisk A/S by 100.3% in the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after buying an additional 11,727,507 shares in the last quarter. FMR LLC lifted its stake in shares of Novo Nordisk A/S by 122.7% in the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after buying an additional 6,654,614 shares in the last quarter. Morgan Stanley lifted its stake in shares of Novo Nordisk A/S by 96.5% in the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares in the last quarter. Finally, Polen Capital Management LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $718,995,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.3 %

Shares of NVO stock opened at $123.04 on Monday. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The stock has a market cap of $552.15 billion, a P/E ratio of 45.36, a P/E/G ratio of 2.05 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company has a 50 day simple moving average of $126.39 and a two-hundred day simple moving average of $111.03.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVO. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Finally, UBS Group began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.